The prognostic value of P53 and CA15.3 tumor markers in breast cancer patient

Document Type : Original Article

Authors

1 Radioisotopes Department, Nuclear Research Center, Egyptian Atomic Energy Authority, Egypt.

2 Department Zoology Faculty of Sciences, Benha University, Egyp

3 Departments of Biotechnology Research Institute, Microbial Biotechnology Division, National Research Centre, 12622, Cairo, Egypt

4 Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University Cairo, Egypt. Medical Oncology Unit, Cairo Oncology Center, Cairo, Egypt

5 Department Zoology Faculty of Sciences, Benha University, Egypt

Abstract

 Breast cancer is the second most prevalent malignancy among women. The cancer antigen
CA 15-3 has been used as a putative serum marker of occult and recurring breast carcinoma
.The p53 gene is mutated in human cancer. Immunohistochemistry reveals that the mutant
p53 protein is more stable and has a longer half-life compared to the wild type. This study
aims to estimate the role of the p53 protein in diagnosing and confirming breast cancer
compared to cancer antigen 15-3 (CA15-3.The current research involved 68 women
diagnosed with breast cancer who were aged 30-60 years old. The control group consisted
of 10 healthy women. Before surgery, sera samples were collected. The Sandwich-ELISA
technique measures the amount of p53 protein in sera. An immunoradiometric assay
(IRMA) kit was used to measure the sera CA 15-3 levels. The study found a higher level of
CA15-3 In breast cancer patients (186.7±218) compared to healthy control groups
(8.88±3.7). There are no significant associations between p53 protein levels and patient
clinical features such as age and grade. Furthermore, the p53 protein value did not correlate
with serum CA 15-3. 

Keywords

Files

Share

How to cite

Statistics